BioMarin Acquires Amicus for $14.50 per Share
BioMarin Pharmaceutical(BMRN) said that it completed the previously announced agreement to acquire Amicus Therapeutics (FOLD) for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8B. BioMarin expects to provide updated FY guidance during its Q1 earnings conference call on May 4.
